Testing new ways to find lung germs in CF
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests a new method to detect bacteria in the lungs of people with cystic fibrosis (CF) by analyzing mucus samples. It aims to improve how we diagnose and treat lung infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older
- You have a confirmed diagnosis of cystic fibrosis
- You can cough up sputum (phlegm from your lungs)
- Your lung function is at least 30% of predicted (based on your age, height, and sex)
- You have not had an organ transplant
- You have not had cancer or cancer treatment in the past year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses advanced diagnostic tests to help people whose cystic fibrosis (CF) diagnosis is unclear. It aims to give a clearer answer about whether you have CF or a related condition.
This study aims to understand what causes and increases the risk of lung infections (exacerbations) in people with cystic fibrosis. It involves regular monitoring and sample collection at home and in the clinic to identify early warning signs.
This study tests a new type of MRI scan that uses either special gas (xenon) or regular MRI to take detailed pictures of the lungs in people with cystic fibrosis. The goal is to see how well these scans can track lung health over time, without using X-ray radiation.
This study uses an MRI (a safe, radiation-free scan) to look at the airways in the lungs of children and teens with cystic fibrosis. It aims to see if MRI can detect changes in airway structure over time.
This trial follows people with cystic fibrosis to better understand how “nontuberculous mycobacteria” (a type of lung germ) spreads between healthcare visits and care settings. It may help improve future prevention and monitoring strategies for CF patients who have had these bacteria.
This study looks at how highly effective CF modulator therapies change the bacteria living in the lungs of people with cystic fibrosis. Understanding these changes may help improve future treatments.
Hear when a new Cystic Fibrosis (CF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.